Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more
Shield Therapeutics plc (SHIEF) - Net Assets
Latest net assets as of June 2025: $-14.86 Million USD
Based on the latest financial reports, Shield Therapeutics plc (SHIEF) has net assets worth $-14.86 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.10 Million) and total liabilities ($76.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.86 Million |
| % of Total Assets | -23.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.35% |
| 10-Year Change | N/A |
| Growth Volatility | 81.04 |
Shield Therapeutics plc - Net Assets Trend (2015–2024)
This chart illustrates how Shield Therapeutics plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shield Therapeutics plc (2015–2024)
The table below shows the annual net assets of Shield Therapeutics plc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.32 Million | -108.76% |
| 2023-12-31 | $15.03 Million | +177.00% |
| 2022-12-31 | $5.43 Million | -86.77% |
| 2021-12-31 | $41.03 Million | +35.53% |
| 2020-12-31 | $30.28 Million | -5.81% |
| 2019-12-31 | $32.15 Million | -20.49% |
| 2018-12-31 | $40.43 Million | -1.89% |
| 2017-12-31 | $41.21 Million | -14.85% |
| 2016-12-31 | $48.40 Million | +359.59% |
| 2015-12-31 | $-18.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shield Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21219500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $258.53 Million | % |
| Total Equity | $-1.32 Million | 100.00% |
Shield Therapeutics plc Competitors by Market Cap
The table below lists competitors of Shield Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZOO Digital Group plc
PINK:ZDGGF
|
$13.76 Million |
|
Hotel Royal Chihpen
TWO:5704
|
$13.77 Million |
|
InBioGen Co Ltd
KO:101140
|
$13.77 Million |
|
Cherrybro co.Ltd
KQ:066360
|
$13.77 Million |
|
Fractal Gaming Group AB
ST:FRACTL
|
$13.76 Million |
|
BuzzFeed Inc
NASDAQ:BZFD
|
$13.76 Million |
|
QUEST RESOUR.HLDG DL-001
F:5ZK
|
$13.75 Million |
|
Ruanyun Edai Technology Inc. Ordinary shares
NASDAQ:RYET
|
$13.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shield Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,033,000 to -1,317,000, a change of -16,350,000 (-108.8%).
- Net loss of 27,182,000 reduced equity.
- New share issuances of 122,000 increased equity.
- Other factors increased equity by 10,710,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.18 Million | -2063.93% |
| Share Issuances | $122.00K | +9.26% |
| Other Changes | $10.71 Million | +813.21% |
| Total Change | $- | -108.76% |
Book Value vs Market Value Analysis
This analysis compares Shield Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.35 | $0.03 | x |
| 2018-12-31 | $0.35 | $0.03 | x |
| 2019-12-31 | $0.27 | $0.03 | x |
| 2020-12-31 | $0.26 | $0.03 | x |
| 2021-12-31 | $0.19 | $0.03 | x |
| 2022-12-31 | $0.02 | $0.03 | x |
| 2023-12-31 | $0.02 | $0.03 | x |
| 2024-12-31 | $0.00 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shield Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -84.47%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-113.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.76 Million |
| 2016 | -31.03% | -4939.47% | 0.01x | 1.08x | $-19.86 Million |
| 2017 | -47.54% | -3075.04% | 0.01x | 1.09x | $-23.71 Million |
| 2018 | -4.44% | -15.10% | 0.27x | 1.07x | $-5.84 Million |
| 2019 | -27.38% | -1223.92% | 0.02x | 1.13x | $-12.01 Million |
| 2020 | -8.69% | -25.32% | 0.32x | 1.07x | $-5.66 Million |
| 2021 | -47.12% | -1272.94% | 0.03x | 1.08x | $-23.44 Million |
| 2022 | -745.24% | -905.40% | 0.20x | 4.07x | $-40.99 Million |
| 2023 | -221.47% | -254.44% | 0.27x | 3.25x | $-34.80 Million |
| 2024 | 0.00% | -84.47% | 0.56x | 0.00x | $-27.05 Million |
Industry Comparison
This section compares Shield Therapeutics plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shield Therapeutics plc (SHIEF) | $-14.86 Million | 0.00% | N/A | $13.76 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |